Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 150-161

  Weiss, J ^a   Sauer, A ^a   Divac, N ^b   Herzog, M ^a   Schwedhelm, E ^c   Boger R H ^c   Haefeli, W E ^a   Benndorf, R A ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ABC transporters; Angiotensin receptor blockers; Drug interactions; P glycoprotein; Telmisartan

Indexed keywords

ABC TRANSPORTER; ANGIOTENSIN RECEPTOR ANTAGONIST; BREAST CANCER RESISTANCE PROTEIN; CANDESARTAN; CANDESARTAN HEXETIL; EMTRICITABINE; EPROSARTAN; GLYCOPROTEIN P; IRBESARTAN; LOSARTAN; MULTIDRUG RESISTANCE PROTEIN 2; OLMESARTAN; PHENOBARBITAL; QUINIDINE; RIFAMPICIN; TELMISARTAN; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS; REAL TIME POLYMERASE CHAIN REACTION;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; BIPHENYL COMPOUNDS; DIGOXIN; FLUORESCEINS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MEMBRANE TRANSPORT PROTEINS; MICE; P-GLYCOPROTEIN; TETRAZOLES; THIOPHENES;

EID: 77951031222     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.699     Document Type: Article

References (56)

1. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13: 379-393.
2. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502. (Pubitemid 24153990)
3. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-1705.
4. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2006; 204: 216-237.
5. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
6. Glaeser H, Fromm MF. Animal models and intestinal drug transport. Expert Opin Drug Metab Toxicol 2008; 4: 347-361. (Pubitemid 351728511)
7. Huls M, Russel FG, Masereeuw R. The role of ABC transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 2009; 328: 3-9.
8. Widder JD, Guzik TJ, Mueller CF et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol 2007; 27: 762-768. (Pubitemid 46606704)
9. Benndorf RA, Böger RH. Pleiotropic effects of telmisartan: still more to come? J Hypertens 2008; 26: 854-856.
10. Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003; 46: 2261-2270. (Pubitemid 36637909)
11. Bajcetic M, Benndorf RA, Appel D et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 2007; 47: 295-304. (Pubitemid 46294712)
12. Ishiguro N, Maeda K, Saito A et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008; 36: 796-805. (Pubitemid 351468387)
13. Miura M, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta 2009; 399: 83-87.
14. Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-4233.
15. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-1581. (Pubitemid 46527547)
16. Schinkel AH,Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
17. Pavek P, Merino G, Wagenaar E et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312: 144-152.
18. Schuetz EG, Beck ET, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318.
19. Weiss J,Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008; 579: 104-109.
20. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863. (Pubitemid 12054507)
21. Fröhlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004; 68: 2409-2416.
22. Weiss J, Rose J, Storch CH et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59: 238-245. (Pubitemid 47072063)
23. Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323: 257-264. (Pubitemid 47443266)
24. Peters T, Lindenmaier H, Haefeli WE, Weiss J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 291-299. (Pubitemid 43119563)
25. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-1763. (Pubitemid 44427479)
26. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
27. Albermann N, Schmitz-Winnenthal FH, Z'graggen K et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-958.
28. Dantzig AH, Shepard RL, Law KL et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999; 290: 854-862.
29. Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
30. Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F2 values. Drug Metab Dispos 2006; 34: 203-207. (Pubitemid 43145021)
31. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
32. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057. (Pubitemid 38620211)
33. Benndorf RA, Rudolph T, Appel D et al. Telmisartan improves insulin sensitivity in non-diabetic patients with essential hypertension. Metabolism 2006; 55: 1159-1164. (Pubitemid 44219053)
34. Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomised, double-blind study. Clin Ther 2004; 26: 1228-1236. (Pubitemid 39445345)
35. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984. (Pubitemid 44837758)
36. Fenner KS, Troutman MD, Kempshall S et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-181.
37. Lindenmaier H, Becker M, Haefeli WE, Weiss J. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 2005; 33: 1576-1579. (Pubitemid 41539950)
38. Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F. Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983; 24: 41-47.
39. Pedersen KE. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand (Suppl.) 1985; 697: 1-40.
40. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668-672.
41. Stangier J, Su CA, Hendriks MG et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000; 40: 1373-1379.
42. Huls M, Brown CD, Windass AS et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008; 73: 220-225.
43. Pfister O, Oikonomopoulos A, Sereti KI et al. Role of the ATP-binding cassette transporter Abcg2 in the phenotype and function of cardiac side population cells. Circ Res 2008; 103: 825-835.
44. Benndorf RA, Gehling UM, Appel D et al. Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension. Stem Cells Dev 2007; 16: 329-338. (Pubitemid 46799509)
45. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002; 41: 7-17.
46. Plosker GL, Foster RH. Eprosartan: A review of its use in the management of hypertension. Drugs 2000; 60: 177-201. (Pubitemid 30598823)
47. Tanaka H, Nagasawa Y, Matsui I et al. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Clin Exp Nephrol 2009; 13: 61-65.
48. Bolbrinker J, Huber M, Scholze J, Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundam Clin Pharmacol 2009; 23: 767-774.
49. Pascolo L, Fernetti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003; 303: 259-265. (Pubitemid 36338234)
50. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 118: 147-150. (Pubitemid 34779530)
51. Zisowsky J, Koegel S, Leyers S et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007; 73: 298-307. (Pubitemid 44855730)
52. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412. (Pubitemid 28477680)
53. Bauer LA, Horn JR, Maxon MS, Easterling TR, Shen DD, StrandnessJr DE. Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition. J Clin Pharmacol 2000; 40: 533-543.
54. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997; 61: 292-300. (Pubitemid 27145430)
55. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529. (Pubitemid 32783749)
56. Croom KF, Plosker GL. Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs 2008; 68: 1543-1569. (Pubitemid 352001192)